News
VRCA
3.580
-10.72%
-0.430
Weekly Report: what happened at VRCA last week (1005-1009)?
Weekly Report · 1d ago
Weekly Report: what happened at VRCA last week (0928-1002)?
Weekly Report · 10/05 09:22
Lake Street Keeps Their Buy Rating on Verrica Pharmaceuticals (VRCA)
TipRanks · 09/30 13:16
Verrica Pharmaceuticals to present new YCANTH data at upcoming conferences
TipRanks · 09/30 12:36
Weekly Report: what happened at VRCA last week (0921-0925)?
Weekly Report · 09/28 09:21
Verrica Pharmaceuticals management to meet virtually with Lake Street
TipRanks · 09/21 15:35
Weekly Report: what happened at VRCA last week (0914-0918)?
Weekly Report · 09/21 09:21
Weekly Report: what happened at VRCA last week (0907-0911)?
Weekly Report · 09/14 09:22
Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
Barchart · 09/10 07:05
Weekly Report: what happened at VRCA last week (0831-0904)?
Weekly Report · 09/07 09:20
One new option listing on September 3rd
TipRanks · 09/03 12:30
Weekly Report: what happened at VRCA last week (0824-0828)?
Weekly Report · 08/31 09:22
Analysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (VRCA) and Amgen (AMGN)
TipRanks · 08/27 15:20
Lake Street starts Verrica Pharmaceuticals with a Buy
TipRanks · 08/27 12:45
Verrica Pharmaceuticals initiated with a Buy at Lake Street
TipRanks · 08/27 12:00
Weekly Report: what happened at VRCA last week (0817-0821)?
Weekly Report · 08/24 09:22
Verrica Pharmaceuticals Earnings Call: Growth Amid Losses
TipRanks · 08/22 00:26
Verrica Pharma Gains: What Is The Buzz?
NASDAQ · 08/19 15:23
Verrica’s Leadership Makes Bold Insider Bet on the Company’s Future
TipRanks · 08/19 02:01
Verrica Pharmaceuticals CEO buys $125.8K in common stock
TipRanks · 08/18 21:10
More
Webull provides a variety of real-time VRCA stock news. You can receive the latest news about Verrica Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About VRCA
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).